When you have led an evacuation of Brits out of the Congo and worked in Khmer Rouge territory with Scotland Yard on a hostage crisis, forging international links with kindred biotech organisations ranks as a slightly less hazardous mission.For Harriet Fear, CEO of One Nucleus – the Cambridge-based Life Science membership body – taking the organisation global was a major objective from Day One and well within her compass following a glittering Foreign Office career.
Her energy and diplomacy combined have seen One Nucleus become a catalyst for collaboration – both within the UK and internationally. Fear delivered an excellent presentation to the Deyton Bell’s recent Transatlantic Business Forum highlighting the global partnerships One Nucleus has formed to date, especially in America.
She proudly paraded a quartet of quality relationships that One Nucleus has effected across the Atlantic and outlined the benefits of links with four major US partners that give Cambridge BioMedTech Cluster companies Coast to Coast credibility.
So far One Nucleus has signed MoUs with powerhouses MassBio and MassMedic on the East Coast and BayBIO and BIOCOM on the West. All the organisations are working together on joint initiatives, cross-pollenating events and leveraging their combined influence and purchasing power.
The intellectual approach Fear has taken into the role has fashioned One Nucleus into a global thought leader in the Life Science arena. The cleverly conceived leadership lecture series One Nucleus devised has been a case in point, bringing focus to key BioMedTech research areas and bringing together world leaders in targeted segments.
The next One Nucleus Life Science Leadership Series event – at Clare College, Cambridge on May 17 – homes in on infectious diseases and vaccines. To see why, address what the following companies have in common – Novartis, Enanta, Bristol Myers Squibb, Inhibitex, Celgene Corporation, Aliva Therapeutics, Gilead, Pharmasset, Roche, Anandys, Vertex and Alios. The answer is that they have all been involved in major Hepatitis C drug development-related deals in the last year, with a collective headline value well over $10 billion.
Fear said: “The size and frequency of announced deals in the Hep C space have been astonishing over recent months. While there is scope for this to continue, it may also serve as an indicator of the growing interest and potential returns available in the anti-infective field with the discovery and development of new strategies of therapeutic intervention. Our event therefore seems timely.”
A world-class speaker list includes plenary speakers from MMV and Novartis along with case studies of novel R & D programmes under development in emerging biotechs which should lead to an exciting day of knowledge sharing, debate and B2B.
For more information and to register as a delegate, visit www.onenucleus.com/infectious-diseases-vaccines
• PHOTOGRAPH SHOWS: Harriet Fear speaking at the Deyton Bell Transatlantic Business Forum. Photograph by: Alan Bennett/Media Imaging Solutions www.mediaimagingsolutions.com